# Kaltura Inc: financial statements, quarterly

KLTR · Nasdaq · CIK 1432133 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kltr.md) · [Financials](/companies/kltr/financials.md) · [Filings](/companies/kltr/filings.md) · [Insiders](/companies/kltr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kltr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [43.5](/filings/0001432133-24-000157.md) | [44.5 d](/filings/0001628280-26-018182.md) | [44.8](/filings/0001432133-25-000051.md) | [44.0](/filings/0001432133-25-000086.md) | [44.3](/filings/0001628280-25-051053.md) | [45.6 d](/filings/0001628280-26-018182.md) | [47.0](/filings/0001628280-26-033466.md) | [44.5](/filings/0001628280-26-052959.md) | [43.9](/filings/0001628280-25-051053.md) | [45.5 d](/filings/0001628280-26-018182.md) | [44.6](/filings/0001628280-26-033466.md) | [46.9](/filings/0001628280-26-052959.md) |
| Cost of revenue | $m | [15.8](/filings/0001432133-24-000157.md) | [15.8 d](/filings/0001628280-26-018182.md) | [16.2](/filings/0001432133-25-000051.md) | [15.4](/filings/0001432133-25-000086.md) | [14.8](/filings/0001628280-25-051053.md) | [13.3 d](/filings/0001628280-26-018182.md) | [14.2](/filings/0001628280-26-033466.md) | [13.2](/filings/0001628280-26-052959.md) | [13.1](/filings/0001628280-25-051053.md) | [12.6 d](/filings/0001628280-26-018182.md) | [12.5](/filings/0001628280-26-033466.md) | [12.4](/filings/0001628280-26-052959.md) |
| Gross profit | $m | [27.7](/filings/0001432133-24-000157.md) | [28.6 d](/filings/0001628280-26-018182.md) | [28.6](/filings/0001432133-25-000051.md) | [28.7](/filings/0001432133-25-000086.md) | [29.5](/filings/0001628280-25-051053.md) | [32.3 d](/filings/0001628280-26-018182.md) | [32.7](/filings/0001628280-26-033466.md) | [31.2](/filings/0001628280-26-052959.md) | [30.7](/filings/0001628280-25-051053.md) | [33.0 d](/filings/0001628280-26-018182.md) | [32.1](/filings/0001628280-26-033466.md) | [34.5](/filings/0001628280-26-052959.md) |
| Research and development | $m | [12.6](/filings/0001432133-24-000157.md) | [12.7 d](/filings/0001628280-26-018182.md) | [12.0](/filings/0001432133-25-000051.md) | [12.0](/filings/0001432133-25-000086.md) | [12.4](/filings/0001628280-25-051053.md) | [13.0 d](/filings/0001628280-26-018182.md) | [12.1](/filings/0001628280-26-033466.md) | [11.6](/filings/0001628280-26-052959.md) | [11.5](/filings/0001628280-25-051053.md) | [10.9 d](/filings/0001628280-26-018182.md) | [10.7](/filings/0001628280-26-033466.md) | [12.7](/filings/0001628280-26-052959.md) |
| Operating income | $m | [(8.3)](/filings/0001432133-24-000157.md) | [(8.8) d](/filings/0001628280-26-018182.md) | [(7.3)](/filings/0001432133-25-000051.md) | [(8.6)](/filings/0001432133-25-000086.md) | [(4.5)](/filings/0001628280-25-051053.md) | [(3.8) d](/filings/0001628280-26-018182.md) | [(1.6)](/filings/0001628280-26-033466.md) | [(2.8)](/filings/0001628280-26-052959.md) | [(1.5)](/filings/0001628280-25-051053.md) | [0.9 d](/filings/0001628280-26-018182.md) | [(1.2)](/filings/0001628280-26-033466.md) | [(0.8)](/filings/0001628280-26-052959.md) |
| Interest expense | $m | [0.8](/filings/0001178913-23-003581.md) | [0.8 d](/filings/0001432133-24-000088.md) | [0.7](/filings/0001432133-24-000111.md) | [0.7](/filings/0001432133-24-000145.md) | [0.7](/filings/0001628280-25-051053.md) | [0.6 d](/filings/0001628280-26-018182.md) | [0.6](/filings/0001628280-26-033466.md) | [0.6](/filings/0001628280-26-052959.md) | [0.5](/filings/0001628280-25-051053.md) | [0.5 d](/filings/0001628280-26-018182.md) | [0.5](/filings/0001628280-26-033466.md) | [0.5](/filings/0001628280-26-052959.md) |
| Income tax | $m | [2.5](/filings/0001432133-24-000157.md) | [1.4 d](/filings/0001628280-26-018182.md) | [2.3](/filings/0001432133-25-000051.md) | [2.5](/filings/0001432133-25-000086.md) | [1.3](/filings/0001628280-25-051053.md) | [1.6 d](/filings/0001628280-26-018182.md) | [1.3](/filings/0001628280-26-033466.md) | [0.4](/filings/0001628280-26-052959.md) | [1.2](/filings/0001628280-25-051053.md) | [0.1 d](/filings/0001628280-26-018182.md) | [2.5](/filings/0001628280-26-033466.md) | [2.5](/filings/0001628280-26-052959.md) |
| Net income | $m | [(10.7)](/filings/0001432133-24-000157.md) | [(12.1) d](/filings/0001628280-26-018182.md) | [(11.1)](/filings/0001432133-25-000051.md) | [(10.0)](/filings/0001432133-25-000086.md) | [(3.6)](/filings/0001628280-25-051053.md) | [(6.6) d](/filings/0001628280-26-018182.md) | [(1.1)](/filings/0001628280-26-033466.md) | [(7.8)](/filings/0001628280-26-052959.md) | [(2.6)](/filings/0001628280-25-051053.md) | [(0.6) d](/filings/0001628280-26-018182.md) | [(3.8)](/filings/0001628280-26-033466.md) | [(5.5)](/filings/0001628280-26-052959.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001432133-24-000157.md) | not reported | not reported | [(0.07)](/filings/0001432133-25-000086.md) | [0.02](/filings/0001628280-25-051053.md) | not reported | [(0.01)](/filings/0001628280-26-033466.md) | [(0.05)](/filings/0001628280-26-052959.md) | [0.02](/filings/0001628280-25-051053.md) | not reported | [(0.03)](/filings/0001628280-26-033466.md) | [(0.04)](/filings/0001628280-26-052959.md) |
| Basic EPS | $ per share | [0.08](/filings/0001432133-24-000157.md) | not reported | [(0.08)](/filings/0001432133-25-000051.md) | [0.07](/filings/0001432133-25-000086.md) | [0.02](/filings/0001628280-25-051053.md) | not reported | [(0.01)](/filings/0001628280-26-033466.md) | [(0.05)](/filings/0001628280-26-052959.md) | [0.02](/filings/0001628280-25-051053.md) | not reported | [(0.03)](/filings/0001628280-26-033466.md) | [(0.04)](/filings/0001628280-26-052959.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue, us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [34.1](/filings/0001432133-24-000157.md) | [36.7](/filings/0001628280-26-018182.md) | [31.6](/filings/0001432133-25-000051.md) | [34.3](/filings/0001432133-25-000086.md) | [36.8](/filings/0001628280-25-051053.md) | [33.1](/filings/0001628280-26-018182.md) | [31.7](/filings/0001628280-26-033466.md) | [35.4](/filings/0001628280-26-052959.md) | [41.5](/filings/0001628280-25-051053.md) | [27.5](/filings/0001628280-26-052959.md) | [58.4](/filings/0001628280-26-033466.md) | [26.0](/filings/0001628280-26-052959.md) |
| Current assets | $m | [109](/filings/0001178913-23-003581.md) | [112](/filings/0001432133-25-000025.md) | [105](/filings/0001432133-24-000111.md) | [108](/filings/0001432133-24-000145.md) | [119](/filings/0001432133-24-000157.md) | [122](/filings/0001628280-26-018182.md) | [101](/filings/0001432133-25-000051.md) | [114](/filings/0001432133-25-000086.md) | [112](/filings/0001628280-25-051053.md) | [90.7](/filings/0001628280-26-052959.md) | [98.6](/filings/0001628280-26-033466.md) | [75.3](/filings/0001628280-26-052959.md) |
| Total assets | $m | [180](/filings/0001178913-23-003581.md) | [184](/filings/0001432133-25-000025.md) | [173](/filings/0001432133-24-000111.md) | [171](/filings/0001432133-24-000145.md) | [179](/filings/0001432133-24-000157.md) | [181](/filings/0001628280-26-018182.md) | [173](/filings/0001432133-25-000051.md) | [169](/filings/0001432133-25-000086.md) | [173](/filings/0001628280-25-051053.md) | [165](/filings/0001628280-26-052959.md) | [160](/filings/0001628280-26-033466.md) | [169](/filings/0001628280-26-052959.md) |
| Current liabilities | $m | [127](/filings/0001178913-23-003581.md) | [99.9](/filings/0001432133-25-000025.md) | [96.9](/filings/0001432133-24-000111.md) | [98.5](/filings/0001432133-24-000145.md) | [106](/filings/0001432133-24-000157.md) | [102](/filings/0001628280-26-018182.md) | [95.8](/filings/0001432133-25-000051.md) | [98.0](/filings/0001432133-25-000086.md) | [101](/filings/0001628280-25-051053.md) | [126](/filings/0001628280-26-052959.md) | [122](/filings/0001628280-26-033466.md) | [134](/filings/0001628280-26-052959.md) |
| Total liabilities | $m | [147](/filings/0001178913-23-003581.md) | [153](/filings/0001432133-25-000025.md) | [148](/filings/0001432133-24-000111.md) | [148](/filings/0001432133-24-000145.md) | [154](/filings/0001432133-24-000157.md) | [157](/filings/0001628280-26-018182.md) | [150](/filings/0001432133-25-000051.md) | [152](/filings/0001432133-25-000086.md) | [155](/filings/0001628280-25-051053.md) | [158](/filings/0001628280-26-052959.md) | [155](/filings/0001628280-26-033466.md) | [167](/filings/0001628280-26-052959.md) |
| Long-term debt | $m | [0.0](/filings/0001178913-23-003581.md) | [33.0](/filings/0001432133-25-000025.md) | [31.7](/filings/0001432133-24-000111.md) | [31.1](/filings/0001432133-24-000145.md) | [30.5](/filings/0001432133-24-000157.md) | [29.2](/filings/0001628280-26-018182.md) | [27.9](/filings/0001432133-25-000051.md) | [26.6](/filings/0001432133-25-000086.md) | [25.3](/filings/0001628280-25-051053.md) | [0.0](/filings/0001628280-26-018182.md) | [27.8](/filings/0001628280-26-033466.md) | [26.7](/filings/0001628280-26-052959.md) |
| Current portion of debt | $m | [31.5](/filings/0001178913-23-003581.md) | [1.6](/filings/0001432133-25-000025.md) | [2.1](/filings/0001432133-24-000111.md) | [2.3](/filings/0001432133-24-000145.md) | [2.5](/filings/0001432133-24-000157.md) | [3.1](/filings/0001628280-26-018182.md) | [3.8](/filings/0001432133-25-000051.md) | [4.4](/filings/0001432133-25-000086.md) | [5.0](/filings/0001628280-25-051053.md) | [29.0](/filings/0001628280-26-052959.md) | [27.8](/filings/0001628280-26-033466.md) | [26.6](/filings/0001628280-26-052959.md) |
| Shareholders' equity | $m | [32.2](/filings/0001432133-24-000157.md) | [30.3](/filings/0001628280-26-018182.md) | [25.1](/filings/0001432133-25-000051.md) | [23.5](/filings/0001628280-25-051053.md) | [24.1](/filings/0001628280-25-051053.md) | [24.4](/filings/0001628280-26-052959.md) | [22.7](/filings/0001628280-26-052959.md) | [17.0](/filings/0001628280-26-052959.md) | [17.7](/filings/0001628280-25-051053.md) | [6.3](/filings/0001628280-26-052959.md) | [4.6](/filings/0001628280-26-052959.md) | [1.7](/filings/0001628280-26-052959.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1.7 d](/filings/0001432133-24-000157.md) | [1.6 d](/filings/0001628280-26-018182.md) | [(1.1)](/filings/0001432133-25-000051.md) | [(1.6) d](/filings/0001432133-25-000086.md) | [10.7 d](/filings/0001628280-25-051053.md) | [4.3 d](/filings/0001628280-26-018182.md) | [(1.0)](/filings/0001628280-26-033466.md) | [2.7 d](/filings/0001628280-26-052959.md) | [9.3 d](/filings/0001628280-25-051053.md) | [3.6 d](/filings/0001628280-26-018182.md) | [0.7](/filings/0001628280-26-033466.md) | [(2.0) d](/filings/0001628280-26-052959.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001432133-24-000157.md) | [0.8 d](/filings/0001628280-26-018182.md) | [0.1](/filings/0001432133-25-000051.md) | [0.2 d](/filings/0001432133-25-000086.md) | [0.1 d](/filings/0001628280-25-051053.md) | [0.1 d](/filings/0001628280-26-018182.md) | [0.3](/filings/0001628280-26-033466.md) | [0.1 d](/filings/0001628280-26-052959.md) | [0.1 d](/filings/0001628280-25-051053.md) | [0.1 d](/filings/0001628280-26-018182.md) | [0.1](/filings/0001628280-26-033466.md) | [0.1 d](/filings/0001628280-26-052959.md) |
| Share repurchases | $m | [0.0 d](/filings/0001432133-24-000157.md) | [0.0 d](/filings/0001628280-26-018182.md) | [0.0](/filings/0001432133-25-000051.md) | [0.1 d](/filings/0001432133-25-000086.md) | [2.1 d](/filings/0001628280-25-051053.md) | [0.7 d](/filings/0001628280-26-018182.md) | [2.3](/filings/0001628280-26-033466.md) | [7.3 d](/filings/0001628280-26-052959.md) | [0.0 d](/filings/0001628280-25-051053.md) | [16.6 d](/filings/0001628280-26-018182.md) | [0.0](/filings/0001628280-26-033466.md) | [0.0 d](/filings/0001628280-26-052959.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2020-06-30) | period not labelled (2021-03-31) | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q3 FY2023 (2023-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [25.2](/filings/0001178913-21-002793.md) | [25.7](/filings/0001432133-22-000012.md) | [32.8](/filings/0001432133-22-000042.md) | [103](/filings/0001432133-22-000059.md) | [128](/filings/0001432133-22-000012.md) | [130](/filings/0001432133-22-000042.md) | [132](/filings/0001178913-23-003581.md) | [139](/filings/0001178913-23-003581.md) | [154](/filings/0001628280-26-033466.md) | [154](/filings/0001628280-26-052959.md) | [146](/filings/0001628280-26-033466.md) | [148](/filings/0001628280-26-052959.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 152,551,223 at 2026-08-03, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-052959.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.